Chelsea Therapeutics, Inc. Resolves Bioavailability Issue and Reports Greater Than 10-Fold Improvement in Relative Bioavailability of New CH-1504 Formulation

CHARLOTTE, N.C., Sept. 10, 2007 (PRIME NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) reported results from its human bioequivalence study quantifying the improvements in relative bioavailability demonstrated by the disodium salt formulation of CH-1504 and identifying the doses to be used in a Phase II evaluation in the treatment of rheumatoid arthritis.